Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RUXOLITINIB Cause Incorrect dose administered? 723 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 723 reports of Incorrect dose administered have been filed in association with RUXOLITINIB (OPZELURA). This represents 1.1% of all adverse event reports for RUXOLITINIB.

723
Reports of Incorrect dose administered with RUXOLITINIB
1.1%
of all RUXOLITINIB reports
49
Deaths
136
Hospitalizations

How Dangerous Is Incorrect dose administered From RUXOLITINIB?

Of the 723 reports, 49 (6.8%) resulted in death, 136 (18.8%) required hospitalization, and 9 (1.2%) were considered life-threatening.

Is Incorrect dose administered Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 723 reports have been filed with the FAERS database.

What Other Side Effects Does RUXOLITINIB Cause?

Off label use (12,492) Death (6,561) Fatigue (5,663) Anaemia (3,593) Haemoglobin decreased (3,297) Platelet count decreased (3,028) Diarrhoea (2,531) Asthenia (2,529) Dizziness (2,398) Pneumonia (2,343)

What Other Drugs Cause Incorrect dose administered?

TIRZEPATIDE (23,301) ADALIMUMAB (14,000) DUPILUMAB (9,907) RANITIDINE (9,337) INSULIN LISPRO (8,318) ACETAMINOPHEN (5,316) DULAGLUTIDE (5,207) SECUKINUMAB (4,524) INSULIN GLARGINE (3,070) SOMATROPIN (2,772)

Which RUXOLITINIB Alternatives Have Lower Incorrect dose administered Risk?

RUXOLITINIB vs SABRIL RUXOLITINIB vs SACCHAROMYCES CEREVISIAE RUXOLITINIB vs SACITUZUMAB GOVITECAN RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY RUXOLITINIB vs SACROSIDASE

Related Pages

RUXOLITINIB Full Profile All Incorrect dose administered Reports All Drugs Causing Incorrect dose administered RUXOLITINIB Demographics